display
Amsterdam (dpa) - Despite rare cases of severe thrombosis, the benefits of the corona vaccine from Astrazeneca are, according to the EU Medicines Agency (EMA), to be rated higher than the risks in all age groups.
Thereafter, the vaccine can continue to be used without restrictions.
The cerebral vein thrombosis occurs on average in one in 100,000 vaccinated people, according to the analysis by the EMA experts, which was presented in Amsterdam today.
On the other hand, there is the very strong reduction in serious Covid 19 diseases.
According to the analysis, the risk of blood clots with a very low number of platelets is higher in people under 60 than in older people.
But even with the younger ones, the advantages predominate.
This includes that far fewer vaccinated people would have to be moved to hospitals and intensive care units.
"The vaccine saves lives," said EMA senior data analyst Peter Arlett.
display
The EMA had previously determined after examining cases of cerebral vein thrombosis that the vaccine could be used without restriction. However, some states had restricted the vaccination and only vaccinated people over the age of 60 with it. The EU Commission commissioned the EMA to carry out the analysis in order to help national health authorities decide on the use of the vaccine. The experts had analyzed data on vaccinations, infection rates, admissions to hospitals and mortality.
In Germany, 59 cases of sinus and cerebral vein thrombosis after vaccination with the corona vaccine from Astrazeneca were reported by mid-April.
Twelve people died.
According to the Robert Koch Institute (RKI), a total of more than 4.2 million first doses and 4153 second doses of the vaccine had been administered up to and including April 15.
© dpa-infocom, dpa: 210423-99-328609 / 5
Information from the EMA